Surrozen, Inc./DE (SRZN) stock
SRZNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$29.98−2.34 (-7.24%)
Close on Nov 17, 2026Market cap $352.37MP/E –Yield –
Surrozen r&d expenses
Research and development expenses are spending on new products and technology.
Surrozen's R&D Expenses for the twelve months ending Jun 30, 2026 was $34.58M, up 49.4% year over year. For fiscal 2025 it was $29.37M, up 39.0% from the year before. The highest annual figure on record is $40.18M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.37M | +39.0% |
| FY2024 | Dec 31, 2024 | $21.13M | -22.4% |
| FY2023 | Dec 31, 2023 | $27.23M | -26.4% |
| FY2022 | Dec 31, 2022 | $37.01M | -7.9% |
| FY2021 | Dec 31, 2021 | $40.18M | +56.4% |
| FY2020 | Dec 31, 2020 | $25.68M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $8.48M | +40.4% |
| Q1 FY2026 | Mar 31, 2026 | $9.33M | +42.2% |
| Q4 FY2025 | Dec 31, 2025 | $8.99M | +68.1% |
| Q3 FY2025 | Sep 30, 2025 | $7.77M | +49.5% |
| Q2 FY2025 | Jun 30, 2025 | $6.04M | -0.9% |
| Q1 FY2025 | Mar 31, 2025 | $6.56M | +7.3% |
| Q4 FY2024 | Dec 31, 2024 | $5.35M | -22.9% |
| Q3 FY2024 | Sep 30, 2024 | $5.20M | -35.7% |
| Q4 FY2023 | Dec 31, 2023 | $6.10M | -35.4% |
| Q3 FY2023 | Sep 30, 2023 | $6.11M | -29.1% |
| Q2 FY2023 | Jun 30, 2023 | $6.94M | -27.6% |
| Q1 FY2023 | Mar 31, 2023 | $8.09M | -13.7% |
| Q4 FY2022 | Dec 31, 2022 | $9.44M | -13.4% |
| Q3 FY2022 | Sep 30, 2022 | $8.62M | -17.2% |
| Q2 FY2022 | Jun 30, 2022 | $9.58M | -6.7% |
| Q1 FY2022 | Mar 31, 2022 | $9.37M | +9.0% |
| Q4 FY2021 | Dec 31, 2021 | $10.89M | +25.9% |
| Q3 FY2021 | Sep 30, 2021 | $10.42M | +49.7% |
| Q2 FY2021 | Jun 30, 2021 | $10.27M | – |
| Q1 FY2021 | Mar 31, 2021 | $8.60M | – |
| Q4 FY2020 | Dec 31, 2020 | $8.65M | – |
| Q3 FY2020 | Sep 30, 2020 | $6.96M | – |
See a number that looks wrong?